241 related articles for article (PubMed ID: 29309592)
1. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination.
Lim AG; Qureshi H; Mahmood H; Hamid S; Davies CF; Trickey A; Glass N; Saeed Q; Fraser H; Walker JG; Mukandavire C; Hickman M; Martin NK; May MT; Averhoff F; Vickerman P
Int J Epidemiol; 2018 Apr; 47(2):550-560. PubMed ID: 29309592
[TBL] [Abstract][Full Text] [Related]
2. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
[TBL] [Abstract][Full Text] [Related]
3. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
4. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
[TBL] [Abstract][Full Text] [Related]
5. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study.
Trickey A; Fraser H; Lim AG; Walker JG; Peacock A; Colledge S; Leung J; Grebely J; Larney S; Martin NK; Degenhardt L; Hickman M; May MT; Vickerman P
J Viral Hepat; 2019 Dec; 26(12):1388-1403. PubMed ID: 31392812
[TBL] [Abstract][Full Text] [Related]
6. Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections.
Ayoub HH; Abu-Raddad LJ
BMJ Open; 2019 May; 9(5):e026600. PubMed ID: 31133586
[TBL] [Abstract][Full Text] [Related]
7. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study.
Walker JG; Kuchuloria T; Sergeenko D; Fraser H; Lim AG; Shadaker S; Hagan L; Gamkrelidze A; Kvaratskhelia V; Gvinjilia L; Aladashvili M; Asatiani A; Baliashvili D; Butsashvili M; Chikovani I; Khonelidze I; Kirtadze I; Kuniholm MH; Otiashvili D; Sharvadze L; Stvilia K; Tsertsvadze T; Zakalashvili M; Hickman M; Martin NK; Morgan J; Nasrullah M; Averhoff F; Vickerman P
Lancet Glob Health; 2020 Feb; 8(2):e244-e253. PubMed ID: 31864917
[TBL] [Abstract][Full Text] [Related]
8. Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago.
Echevarria D; Gutfraind A; Boodram B; Layden J; Ozik J; Page K; Cotler SJ; Major M; Dahari H
Vaccine; 2019 May; 37(19):2608-2616. PubMed ID: 30962092
[TBL] [Abstract][Full Text] [Related]
9. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
[TBL] [Abstract][Full Text] [Related]
10. What is required for achieving hepatitis C virus elimination in Singapore? A modeling study.
Chaillon A; Thurairajah PH; Hsiang JC; Martin NK
J Gastroenterol Hepatol; 2021 Apr; 36(4):1110-1117. PubMed ID: 32777859
[TBL] [Abstract][Full Text] [Related]
11. Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis.
Lim AG; Walker JG; Mafirakureva N; Khalid GG; Qureshi H; Mahmood H; Trickey A; Fraser H; Aslam K; Falq G; Fortas C; Zahid H; Naveed A; Auat R; Saeed Q; Davies CF; Mukandavire C; Glass N; Maman D; Martin NK; Hickman M; May MT; Hamid S; Loarec A; Averhoff F; Vickerman P
Lancet Glob Health; 2020 Mar; 8(3):e440-e450. PubMed ID: 32087176
[TBL] [Abstract][Full Text] [Related]
12. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
[TBL] [Abstract][Full Text] [Related]
13. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
14. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
Lim AG; Scott N; Walker JG; Hamid S; Hellard M; Vickerman P
PLoS Med; 2021 Oct; 18(10):e1003818. PubMed ID: 34665815
[TBL] [Abstract][Full Text] [Related]
15. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
[TBL] [Abstract][Full Text] [Related]
16. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
[TBL] [Abstract][Full Text] [Related]
17. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?
Lanièce Delaunay C; Godin A; Kronfli N; Panagiotoglou D; Cox J; Alary M; Klein MB; Maheu-Giroux M
Int J Drug Policy; 2021 Oct; 96():103343. PubMed ID: 34215459
[TBL] [Abstract][Full Text] [Related]
18. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
[TBL] [Abstract][Full Text] [Related]
19. HepFREEPak: protocol for a multi-centre, prospective observational study examining efficacy and impact of current therapies for the treatment of hepatitis C in Pakistan and reporting resistance to antiviral drugs: study protocol.
Arif A; Hasnain A; Chaudhry A; Asim M; Shafqat MN; Altaf A; Saba N; Kemos P; Ansari MA; Barnes E; Metcalfe C; Vickerman P; Qureshi H; Hamid S; Choudhry AA; Niaz SK; Foster GR; Choudhry N
BMC Public Health; 2023 Dec; 23(1):2529. PubMed ID: 38110885
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
Durham DP; Skrip LA; Bruce RD; Vilarinho S; Elbasha EH; Galvani AP; Townsend JP
Clin Infect Dis; 2016 Feb; 62(3):298-304. PubMed ID: 26628566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
